Therapy Packs One-Two Punch Against Melanoma

                   
emaxhealth.com     May 20, 2008            

Skin Cancer Symptoms and Treatment Disabling a protein frequently found in melanoma tumors may make the cancer more vulnerable to chemotherapy, according to a pilot study led by researchers in the Duke Comprehensive Cancer Center. "We tested a compound that can weaken the tumor by targeting a... [read full story]                

Full Coverage

Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.

biowizard.com     May 19, 2008          

Departments of Surgery, Pathology, Pharmacology and Cancer Biology, and Medicine, and Institute for Genome Sciences and Policy, Duke University. Malignant transformation in melanoma is characterized by a phenotype "switch" from E- to N-cadherin, which is associated with increased motility and...                

comments

                   

Adherex Announces ASCO Abstract of ADH-1 in Melanoma

marketwire.com     May 19, 2008          

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - May 19, 2008) - Adherex Technologies Inc. (AMEX:ADH)(TSX:AHX), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today the publication of an abstract on the phase I/II study of ADH-1 in combination...                

comments

                   

Adherex Announces ASCO Abstract of ADH-1 in Melanoma (Marketwire)

yahoo.com     May 19, 2008          

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(MARKET WIRE)--May 19, 2008 -- Adherex Technologies Inc. (AMEX: ), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today the publication of an abstract on the phase I/II study of ADH-1 in combination with isolated...                

comments

                   

Adherex Technologies Inc.: Adherex Announces ASCO Abstract of ADH-1 in Melanoma

marketwire.com     May 19, 2008          

RESEARCH TRIANGLE PARK, NORTH CAROLINA (MARKET WIRE) Adherex Technologies Inc. (AMEX: ADH)(TSX: AHX), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today the publication of an abstract on the phase I/II study of ADH-1 in combination with isolated limb...                

comments

                   

New Treatment for Deadly Melanoma

ivanhoe.com     May 20, 2008          

One of the deadliest and most highly diagnosed malignant melanomas is vulnerable to a combination of chemotherapy and a protein-disabling drug, according to a new study. Researchers at Duke University’s Comprehensive Cancer Center were able to reduce melanoma tumors in rats 30-fold by first...                

comments